Medical device maker Abbott Laboratories maintained its annual profit forecast on Wednesday and said it expected the U.S.

U.S. stock index futures on Wednesday slumped on fresh trade wars worries with China. Here are some stocks to watch on ...

Continuous glucose monitoring devices could overstate blood sugar levels, with a study revealing inconsistencies in readings compared with traditional methods.

Once-weekly basal insulin combined with an intermittently scanned continuous glucose monitor reduced HbA1c and improved time ...

The battle to claim the continuous glucose monitor with the longest wear time continues with Dexcom Inc.’s G7 15 Day continuous glucose monitor gaining U.S. FDA clearance on April 10 for adults with ...

Dexcom has been cash flow positive for since 2014 and more recently moved into positive earnings territory. While revenue has grown very quickly, research and development expenses and selling, general ...

The longer wear time should improve Dexcom’s margins and help it compete with Abbott, RBC Capital Markets analyst Shagun Singh said.

Libre Drives Diabetes Care: Abbott’s Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

In a world where diabetes management is evolving at a rapid pace, the spotlight shines on non-invasive glucose monitors that promise to change the game.

Abbott’s ABT diversified business portfolio is well-positioned to drive continued momentum in 2024. The stock carries a Zacks ...

Tyler, the Creator addressed criticism over his “That Guy” freestyle on Kendrick Lamar’s beat, calling detractors clueless. He addressed the controversy during his latest interview with ...

The 22-year-old freestyle skier from the People's Republic of China topped qualification with an impressive performance on Friday (28 March) in Engadin, Switzerland. Li pipped two-time world medallist ...